VIDEO: ‘Practice-changing’ AI-derived biomarker can tailor ADT in high-risk prostate cancer

ByIrimar Waters

Fact checked byKatrina Altersitz

CHICAGO — In this Healio video exclusive, Andrew Armstrong, MD, discusses his presentation from the Genitourinary Cancer session at the ASCO Annual meeting.
Armstrong, medical oncologist at Duke Cancer Institute Center for prostate and urologic cancers, presented the results from the use of an AI- derived biomarker in the phase 3 NRG/RTOG 9202 trial for patients with localized high-risk prostate cancer.
“We both developed and validated an AI digital pathology-based biomarker in conjunction with clinical parameters that was able to predict the benefits of long-term ADT,” Armstrong said. “About a third of our patients with high-risk disease could be spared the long-term side effects of androgen deprivation therapy and would have excellent outcomes with short-term ADT. ... This is a practice-changing phase 3 trial.”
Reference:

Armstrong A, et al. Abstract 5001. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago

Published by:

Sources/Disclosures

Collapse

Source:

Healio interviews

Disclosures: Armstrong reports consulting and funding from Astellas Scientific and Medical Affairs Inc, Amgen, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Constellation Pharmaceuticals, Dendreon, Epic Sciences, Exelixis, FORMA Therapeutics, Gilead Sciences, GoodRx, IDEAYA Biosciences, Janssen, Merck, Myovant Sciences, Novartis, Pfizer, and Roche/Genentech.

Take Homes in Prostate Cancer

Read more

VIDEO: ‘Practice-changing’ AI-derived biomarker can tailor ADT in high-risk prostate cancer

Related Content